Nancy L Bartlett

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1662737/publications.pdf

Version: 2024-02-01

369 papers	29,635 citations	9786 73 h-index	5539 163 g-index
375 all docs	375 docs citations	375 times ranked	20724 citing authors

#	Article	IF	Citations
1	Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. New England Journal of Medicine, 2017, 377, 2531-2544.	27.0	3,865
2	Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1â€“2 trial. Lancet Oncology, The, 2019, 20, 31-42.	10.7	1,467
3	Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. New England Journal of Medicine, 2018, 378, 1396-1407.	27.0	1,443
4	Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma. Journal of Clinical Oncology, 2012, 30, 2183-2189.	1.6	1,332
5	Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas. New England Journal of Medicine, 2010, 363, 1812-1821.	27.0	1,266
6	Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2015, 373, 2425-2437.	27.0	1,261
7	Randomized Controlled Trial of Yttrium-90â€“Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkinâ€™s Lymphoma. Journal of Clinical Oncology, 2002, 20, 2453-2463.	1.6	1,069
8	Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study. Journal of Clinical Oncology, 2012, 30, 2190-2196.	1.6	890
9	CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkinâ€™s Lymphoma. New England Journal of Medicine, 2018, 379, 1711-1721.	27.0	796
10	Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. New England Journal of Medicine, 2018, 379, 2517-2528.	27.0	706
11	Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkinâ€™s Lymphoma. New England Journal of Medicine, 2018, 378, 331-344.	27.0	564
12	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet, The, 2019, 393, 229-240.	13.7	517
13	Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. Molecular Therapy, 2017, 25, 285-295.	8.2	498
14	Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncology, The, 2016, 17, 200-211.	10.7	373
15	Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood, 2014, 123, 3095-3100.	1.4	280
16	Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood, 2018, 131, 1183-1194.	1.4	276
17	Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. Journal of Clinical Oncology, 2019, 37, 1790-1799.	1.6	266
18	Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma. New England Journal of Medicine, 2018, 379, 934-947.	27.0	264

#	Article	IF	Citations
19	Stanford V and Radiotherapy for Locally Extensive and Advanced Hodgkinâ€™s Disease: Mature Results of a Prospective Clinical Trial. Journal of Clinical Oncology, 2002, 20, 630-637.	1.6	261
20	Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood, 2002, 99, 4336-4342.	1.4	257
21	Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496). Journal of Clinical Oncology, 2013, 31, 684-691.	1.6	256
22	Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood, 2015, 125, 1394-1402.	1.4	242
23	US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucoseâ€“Positron Emission Tomography Imaging: Southwest Oncology Group S0816. Journal of Clinical Oncology, 2016, 34, 2020-2027.	1.6	239
24	A Phase II study of SGNâ€30 (antiâ€CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. British Journal of Haematology, 2009, 146, 171-179.	2.5	230
25	Bendamustine is effective therapy in patients with rituximabâ€refractory, indolent Bâ€cell nonâ€Hodgkin lymphoma. Cancer, 2010, 116, 106-114.	4.1	217
26	A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies. Clinical Cancer Research, 2012, 18, 248-255.	7.0	204
27	Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood, 2003, 101, 4285-4289.	1.4	191
28	A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. Blood, 2008, 111, 1848-1854.	1.4	189
29	Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood, 2012, 120, 3280-3287.	1.4	188
30	Immunochemotherapy and Autologous Stem-Cell Transplantation for Untreated Patients With Mantle-Cell Lymphoma: CALGB 59909. Journal of Clinical Oncology, 2009, 27, 6101-6108.	1.6	182
31	A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood, 2011, 118, 5119-5125.	1.4	181
32	Gene Expressionâ€“Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin Lymphoma. Journal of Clinical Oncology, 2013, 31, 692-700.	1.6	176
33	Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood, 2017, 130, 2709-2717.	1.4	176
34	Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). Journal of Clinical Oncology, 2015, 33, 3635-3640.	1.6	163
35	Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalinâ„¢ radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Critical Reviews in Oncology/Hematology, 2001, 39, 181-194.	4.4	161
36	Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). Blood, 2015, 126, 851-857.	1.4	161

#	Article	IF	Citations
37	Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. Journal of Clinical Oncology, 2022, 40, 481-491.	1.6	160
38	Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30⁺ Peripheral T-Cell Lymphomas: Results of a Phase I Study. Journal of Clinical Oncology, 2014, 32, 3137-3143.	1.6	153
39	Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and) Tj ETQq1 1 0.784314 rgBT /Overloc prospective, multicentre, single-arm phase 2 study. Lancet Haematology,the, 2018, 5, e609-e617.	4.6	152
40	Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines. Blood, 2019, 134, 6-6.	1.4	152
41	18F-FDG PET/CT for Early Response Assessment in Diffuse Large B-Cell Lymphoma: Poor Predictive Value of International Harmonization Project Interpretation. Journal of Nuclear Medicine, 2011, 52, 386-392.	5.0	151
42	Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. Blood, 2017, 129, 473-483.	1.4	147
43	Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. Journal of Hematology and Oncology, 2014, 7, 24.	17.0	144
44	In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma. Cancer Discovery, 2018, 8, 1258-1269.	9.4	136
45	CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas. Blood, 2020, 136, 2308-2318.	1.4	133
46	The IL-15-Based ALT-803 Complex Enhances FcÎ³RIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas. Clinical Cancer Research, 2016, 22, 596-608.	7.0	130
47	Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. Blood, 2018, 131, 182-190.	1.4	130
48	Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227. Journal of Clinical Oncology, 2016, 34, 1620-1625.	1.6	121
49	Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncology, The, 2022, 23, 1055-1065.	10.7	119
50	Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial. Blood, 2013, 121, 3547-3553.	1.4	117
51	The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and <scp>S</scp>tanford <scp>V</scp> in older <scp>H</scp>odgkin lymphoma patients: a comprehensive analysis from the <scp>N</scp>orth <scp>A</scp>merican intergroup trial <scp>E</scp>2496. British Journal of Haematology, 2013, 161, 76-86.	2.5	111
52	Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica, 2018, 103, 1502-1510.	3.5	111
53	Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. Blood, 2021, 138, 427-438.	1.4	109
54	Hodgkin lymphoma. Nature Reviews Disease Primers, 2020, 6, 61.	30.5	103

#	Article	IF	Citations
55	Assessment of the Stanford V Regimen and Consolidative Radiotherapy for Bulky and Advanced Hodgkinâ€™s Disease: Eastern Cooperative Oncology Group Pilot Study E1492. Journal of Clinical Oncology, 2000, 18, 972-972.	1.6	101
56	Outcomes of adults and children with primary mediastinal Bâ€cell lymphoma treated with doseâ€adjusted <scp>EPOCH</scp>â€R. British Journal of Haematology, 2017, 179, 739-747.	2.5	101
57	Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1bâ€“2 study. Lancet Oncology, The, 2019, 20, 998-1010.	10.7	101
58	NCCN GuidelinesÂ® Insights: B-Cell Lymphomas, Version 5.2021. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 1218-1230.	4.9	98
59	Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkinâ€™s Lymphoma. New England Journal of Medicine, 2022, 387, 310-320.	27.0	98
60	Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. Journal of Clinical Oncology, 2015, 33, 2399-2404.	1.6	97
61	Mature Results of a Phase II Study of Rituximab Therapy for Nodular Lymphocyteâ€“Predominant Hodgkin Lymphoma. Journal of Clinical Oncology, 2014, 32, 912-918.	1.6	96
62	A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large Bâ€cell lymphoma. Cancer, 2012, 118, 3128-3134.	4.1	95
63	Lymphoma Occurring During Pregnancy: Antenatal Therapy, Complications, and Maternal Survival in a Multicenter Analysis. Journal of Clinical Oncology, 2013, 31, 4132-4139.	1.6	93
64	Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma. Journal of Clinical Oncology, 2020, 38, 2519-2529.	1.6	93
65	Prognostic Significance of FDG-PET in Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Standard Salvage Chemotherapy and Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 1646-1652.	2.0	92
66	A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. Blood, 2020, 136, 2401-2409.	1.4	92
67	CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood, 2018, 132, 1013-1021.	1.4	90
68	Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood, 2020, 135, 2106-2109.	1.4	90
69	Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large Bâ€cell lymphoma. British Journal of Haematology, 2021, 194, 690-700.	2.5	88
70	Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. Blood, 2019, 134, 1238-1246.	1.4	86
71	Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Blood, 2020, 135, 735-742.	1.4	86
72	Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematology,the, 2021, 8, e410-e421.	4.6	83

#	Article	IF	Citations
73	Phase III Randomized Study of R-CHOP Versus DA-EPOCH-R and Molecular Analysis of Untreated Diffuse Large B-Cell Lymphoma: CALGB/Alliance 50303. Blood, 2016, 128, 469-469.	1.4	79
74	Increased Body Mass Index Is Associated With Improved Survival in United States Veterans With Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2012, 30, 3217-3222.	1.6	78
75	Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. Lancet Haematology,the, 2017, 4, e176-e182.	4.6	77
76	Assessment of Cellular Proliferation in Tumors by PET Using ¹⁸F-ISO-1. Journal of Nuclear Medicine, 2013, 54, 350-357.	5.0	76
77	A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. Journal of Hematology and Oncology, 2014, 7, 44.	17.0	76
78	Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma. Journal of Clinical Oncology, 2014, 32, 1797-1803.	1.6	75
79	Positron Emission Tomographyâ€"Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. Journal of Clinical Oncology, 2020, 38, 3003-3011.	1.6	75
80	Gray zone lymphoma with features intermediate between classical <scp>H</scp>odgkin lymphoma and diffuse large <scp>B</scp>â€cell lymphoma: <scp>C</scp>haracteristics, outcomes, and prognostication among a large multicenter cohort. American Journal of Hematology, 2015, 90, 778-783.	4.1	71
81	A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma. Clinical Cancer Research, 2016, 22, 1059-1066.	7.0	71
82	High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis. Leukemia and Lymphoma, 2014, 55, 1345-1349.	1.3	67
83	Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: Cancer and leukemia Group B protocol 50206. Leukemia and Lymphoma, 2007, 48, 1313-1319.	1.3	64
84	A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). European Journal of Cancer, 2016, 54, 11-17.	2.8	63
85	Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial. Blood, 2020, 135, 2224-2234.	1.4	62
86	A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma. Blood, 2019, 133, 1201-1204.	1.4	58
87	Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood, 2011, 117, 5314-5320.	1.4	56
88	Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103. Blood, 2016, 128, 2510-2516.	1.4	56
89	Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas. Blood, 2018, 131, 2120-2124.	1.4	56
90	Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial. Lancet Haematology,the, 2020, 7, e808-e815.	4.6	55

#	Article	IF	Citations
91	Interim [¹⁸F]fluorodeoxyglucose positron emission tomography imaging in stage Iâ€“II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?. Leukemia and Lymphoma, 2012, 53, 2143-2150.	1.3	54
92	Evaluation of the International Prognostic Score (IPSâ€7) and a Simpler Prognostic Score (IPSâ€3) for advanced Hodgkin lymphoma in the modern era. British Journal of Haematology, 2015, 171, 530-538.	2.5	54
93	Assessment of knowledge about cancer pain management by physicians in training. Journal of Pain and Symptom Management, 1997, 14, 21-28.	1.2	53
94	CD163 Immunohistochemistry Is Superior to CD68 in Predicting Outcome in Classical Hodgkin Lymphoma. American Journal of Clinical Pathology, 2014, 141, 381-387.	0.7	51
95	Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy. Leukemia and Lymphoma, 2014, 55, 2328-2334.	1.3	48
96	Splenic Pathology in Myelodysplasia. American Journal of Surgical Pathology, 1998, 22, 1255-1266.	3.7	48
97	Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study. Blood, 2018, 132, 399-399.	1.4	48
98	Anti-CD30 Antibodies for Hodgkin Lymphoma. Current Hematologic Malignancy Reports, 2010, 5, 140-147.	2.3	47
99	Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma. Journal of Geriatric Oncology, 2015, 6, 211-218.	1.0	47
100	Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis. Cancer, 2018, 124, 136-144.	4.1	47
101	Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. Leukemia and Lymphoma, 2017, 58, 1607-1616.	1.3	46
102	Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. Leukemia and Lymphoma, 2012, 53, 2283-2286.	1.3	44
103	CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder. American Journal of Transplantation, 2021, 21, 809-814.	4.7	44
104	Mosunetuzumab Shows Promising Efficacy in Patients with Multiply Relapsed Follicular Lymphoma: Updated Clinical Experience from a Phase I Dose-Escalation Trial. Blood, 2020, 136, 42-44.	1.4	44
105	Brentuximab Vedotin in Transplant-NaÃ¯ve Patients with Relapsed or Refractory Hodgkin Lymphoma: Analysis of Two Phase I Studies. Oncologist, 2012, 17, 1073-1080.	3.7	42
106	Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. Blood Advances, 2021, 5, 4149-4155.	5.2	42
107	Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19).. Journal of Clinical Oncology, 2017, 35, 3025-3025.	1.6	42
108	Brentuximab Vedotin and Crizotinib in Anaplastic Large-Cell Lymphoma. Cancer Journal (Sudbury, Mass) Tj ETQq0 0 0 rgBT /Overlock 10	2.0	41

#	Article	IF	Citations
109	Progressive multifocal leukoencephalopathy treated with nivolumab. Journal of NeuroVirology, 2019, 25, 284-287.	2.1	40
110	Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood Advances, 2020, 4, 858-867.	5.2	40
111	First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas. Clinical Cancer Research, 2020, 26, 2524-2534.	7.0	40
112	Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R in MYC-Rearranged Aggressive B-Cell Lymphoma. Blood, 2014, 124, 395-395.	1.4	40
113	Phase II Study of SGN-30 (Anti-CD30 Monoclonal Antibody) in Patients with Refractory or Recurrent Hodgkinâ€™s Disease.. Blood, 2004, 104, 2635-2635.	1.4	39
114	Brentuximab vedotin for the treatment of CD30⁺lymphomas. Immunotherapy, 2011, 3, 475-485.	2.0	37
115	Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial. Leukemia and Lymphoma, 2015, 56, 2569-2578.	1.3	36
116	Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501). Leukemia and Lymphoma, 2015, 56, 958-964.	1.3	36
117	Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia. Blood, 2016, 128, 234-234.	1.4	36
118	Bone marrow staging in patients with non-hodgkin's lymphoma. , 1998, 82, 1154-1159.		35
119	Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study. Blood, 2019, 133, 1762-1765.	1.4	35
120	Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study. British Journal of Haematology, 2014, 165, 510-518.	2.5	34
121	Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial. Journal of Clinical Oncology, 2015, 33, 1936-1942.	1.6	33
122	A Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results In Patients With DLBCL and Other B-Cell Lymphomas. Blood, 2013, 122, 848-848.	1.4	33
123	Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy As Frontline Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell Lymphomas. Blood, 2012, 120, 60-60.	1.4	32
124	Serum Markers in Germ Cell Neoplasms. Hematology/Oncology Clinics of North America, 1991, 5, 1245-1260.	2.2	31
125	Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma. Cancer, 2001, 92, 207-217.	4.1	31
126	Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations. Journal of the National Cancer Institute, 2017, 109, djw249.	6.3	31

#	Article	IF	Citations
127	Multiple Complete Responses in a Phase 1 Dose-Escalation Study of the Antibody-Drug Conjugate SGN-35 in Patients with Relapsed or Refractory CD30-Positive Lymphomas.. Blood, 2008, 112, 1006-1006.	1.4	31
128	Radiation Dosimetry Results From a Phase II Trial of Ibritumomab Tiuxetan (Zevalinâ„¢) Radioimmunotherapy for Patients With Non-Hodgkin's Lymphoma and Mild Thrombocytopenia. Cancer Biotherapy and Radiopharmaceuticals, 2003, 18, 165-178.	1.0	30
129	Blinatumomab for the treatment of B-cell lymphoma. Expert Opinion on Investigational Drugs, 2015, 24, 715-724.	4.1	30
130	Longâ€term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated nonâ€Hodgkin lymphoma. British Journal of Haematology, 2017, 178, 250-256.	2.5	30
131	Ibrutinib Monotherapy in Relapsed/Refractory Follicular Lymphoma (FL): Preliminary Results of a Phase 2 Consortium (P2C) Trial. Blood, 2014, 124, 800-800.	1.4	30
132	Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1. Blood, 2016, 128, LBA-6-LBA-6.	1.4	30
133	Limited utility of routine surveillance imaging for classical Hodgkin lymphoma patients in first complete remission. Cancer, 2014, 120, 2122-2129.	4.1	29
134	Unexpected and Serious Toxicity Observed with Combined Idelalisib, Lenalidomide and Rituximab in Relapsed/Refractory B Cell Lymphomas: Alliance A051201 and A051202. Blood, 2014, 124, 3091-3091.	1.4	28
135	Intravascular lymphoma associated with endocrine dysfunction: a report of four cases and a review of the literature. American Journal of Medicine, 1999, 107, 169-176.	1.5	27
136	Modern treatment of Hodgkin lymphoma. Current Opinion in Hematology, 2008, 15, 408-414.	2.5	27
137	The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance). Leukemia and Lymphoma, 2013, 54, 1405-1410.	1.3	27
138	The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials. Cancer Medicine, 2019, 8, 165-173.	2.8	27
139	Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy. Blood, 2021, 138, 639-639.	1.4	27
140	Thalidomide has limited singleâ€agent activity in relapsed or refractory indolent nonâ€Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B. British Journal of Haematology, 2008, 140, 313-319.	2.5	26
141	A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254. Leukemia and Lymphoma, 2011, 52, 587-596.	1.3	26
142	Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma. Clinical Cancer Research, 2019, 25, 1718-1726.	7.0	26
143	Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia and Lymphoma, 2020, 61, 3188-3197.	1.3	26
144	Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma. Clinical Cancer Research, 2021, 27, 3339-3350.	7.0	26

#	Article	IF	Citations
145	A Phase 2 Multicenter Trial of KTE-C19 (anti-CD19 CAR T Cells) in Patients With Chemorefractory Primary Mediastinal B-Cell Lymphoma (PMBCL) and Transformed Follicular Lymphoma (TFL): Interim Results From ZUMA-1. Blood, 2016, 128, 998-998.	1.4	26
146	Pharmacodynamic Effects and Immune Correlates of Response to the CD20/CD3 Bispecific Antibody Mosunetuzumab in Relapsed or Refractory Non-Hodgkin Lymphoma. Blood, 2019, 134, 1585-1585.	1.4	26
147	Cyclin D1 as an Aid in the Diagnosis of Mantle Cell Lymphoma in Skin Biopsies: A Case Report. American Journal of Dermatopathology, 2001, 23, 470-476.	0.6	25
148	CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas. Expert Opinion on Investigational Drugs, 2018, 27, 601-611.	4.1	25
149	Three-Year Survival Results From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Systemic Anaplastic Large Cell Lymphoma. Blood, 2013, 122, 1809-1809.	1.4	24
150	Interdigitating dendritic reticulum cell tumor of lymph nodes: Case report with differential diagnostic considerations. Diagnostic Cytopathology, 2003, 28, 278-281.	1.0	23
151	A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 347-353.	0.4	23
152	Bortezomib Maintenance (BM) Versus Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): CALGB (Alliance) 50403. Blood, 2015, 126, 337-337.	1.4	23
153	Predictive Factors and Outcomes for Ibrutinib Therapy in Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter Cohort Study. Blood, 2020, 136, 35-36.	1.4	23
154	A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma. Expert Opinion on Drug Safety, 2016, 15, 875-882.	2.4	22
155	The Antibody-Drug Conjugate Brentuximab Vedotin (SGN-35) Induced Multiple Objective Responses in Patients with Relapsed or Refractory CD30-Positive Lymphomas in a Phase 1 Weekly Dosing Study.. Blood, 2009, 114, 2731-2731.	1.4	22
156	Clinical and biologic covariates of outcomes in ZUMA-1: A pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (r-NHL).. Journal of Clinical Oncology, 2017, 35, 7512-7512.	1.6	22
157	Initial Results of US Intergroup Trial of Response-Adapted Chemotherapy or Chemotherapy/Radiation Therapy Based on PET for Non-Bulky Stage I and II Hodgkin Lymphoma (HL) (CALGB/Alliance 50604). Blood, 2015, 126, 578-578.	1.4	21
158	Parameters for Validating a Hospital Pneumatic Tube System. Clinical Chemistry, 2019, 65, 694-702.	3.2	20
159	Activity and tolerabilty of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: Initial phase 1b/2 results.. Journal of Clinical Oncology, 2018, 36, 7504-7504.	1.6	20
160	Managing cytokine release syndrome (CRS) and neurotoxicity with step-fractionated dosing of mosunetuzumab in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL).. Journal of Clinical Oncology, 2019, 37, 7518-7518.	1.6	20
161	Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received â‰¥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study. Blood, 2021, 138, 127-127.	1.4	20
162	Anaplastic Large-Cell Lymphoma With Aberrant Expression of Multiple Cytokeratins Masquerading As Metastatic Carcinoma of Unknown Primary. Journal of Clinical Oncology, 2013, 31, e443-e445.	1.6	19

#	Article	IF	Citations
163	Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by Hans criteria. Leukemia and Lymphoma, 2016, 57, 1191-1193.	1.3	18
164	Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients. Blood, 2018, 131, 1698-1703.	1.4	18
165	Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: <scp>CALGB</scp>/Alliance 50403. American Journal of Hematology, 2020, 95, 583-593.	4.1	18
166	Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202. Blood, 2018, 132, 6-6.	1.4	18
167	Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study. Blood, 2019, 134, 238-238.	1.4	18
168	A Randomized Phase III Trial of ABVD Vs. Stanford V +/â˜ Radiation Therapy In Locally Extensive and Advanced Stage Hodgkin's Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperatve Oncology Group (E2496). Blood, 2010, 116, 415-415.	1.4	18
169	Role of Routine Imaging in Lymphoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 575-584.	4.9	18
170	Rituximab is associated with improved survival in Burkitt lymphoma: a retrospective analysis from two US academic medical centers. Therapeutic Advances in Hematology, 2014, 5, 3-12.	2.5	17
171	Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL. Blood, 2022, 139, 1147-1159.	1.4	17
172	Results of a Prospective Phase II Trial of Limited and Extended Rituximab Treatment in Nodular Lymphocyte Predominant Hodgkinâ€™s Disease (NLPHD).. Blood, 2007, 110, 644-644.	1.4	17
173	Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma. Blood, 2016, 128, 1105-1105.	1.4	17
174	Phase 1/dose expansion trial of brentuximab vedotin andÂlenalidomide in relapsed or refractory diffuse large B-cell lymphoma. Blood, 2022, 139, 1999-2010.	1.4	17
175	Antibodies for the treatment of diffuse large cell lymphoma. Seminars in Oncology, 2003, 30, 448-456.	2.2	15
176	Therapy of Relapsed Hodgkin Lymphoma. Blood Reviews, 2007, 21, 233-243.	5.7	15
177	Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma. Leukemia and Lymphoma, 2012, 53, 506-507.	1.3	15
178	Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration. American Journal of Hematology, 2016, 91, 894-899.	4.1	15
179	Chimeric Antigen Receptor T-Cell Therapy. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 1092-1106.	4.9	15
180	Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies. Cancer, 2002, 95, 2223-2229.	4.1	14

#	Article	IF	Citations
181	Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial. Lancet Haematology,the, 2020, 7, e490-e497.	4.6	14
182	Four-Year Survival Data from an Ongoing Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. Blood, 2014, 124, 3095-3095.	1.4	14
183	Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R. Blood, 2015, 126, 342-342.	1.4	14
184	Results of an Ongoing Phase 2 Study of Brentuximab Vedotin with Rchp As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL). Blood, 2016, 128, 104-104.	1.4	14
185	Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study. Lancet Haematology,the, 2021, 8, e818-e827.	4.6	14
186	Randomized Phase II/III Study of DA-EPOCH-R +/- Venetoclax in Previously Untreated Double Hit Lymphoma: Initial Results from Alliance A051701. Blood, 2021, 138, 523-523.	1.4	14
187	Drug development for recurrent and refractory classical Hodgkin lymphoma. Leukemia and Lymphoma, 2009, 50, 529-540.	1.3	13
188	PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001. Blood, 2019, 134, 349-349.	1.4	13
189	Poor Predictive Value of FDG-PET/CT Performed after 2 Cycles of R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLCL). Blood, 2008, 112, 371-371.	1.4	13
190	Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. Blood, 2010, 116, 961-961.	1.4	13
191	SD-101, a Novel Class C CpG-Oligodeoxynucleotide (ODN) Toll-like Receptor 9 (TLR9) Agonist, Given with Low Dose Radiation for Untreated Low Grade B-Cell Lymphoma: Interim Results of a Phase 1/2 Trial. Blood, 2016, 128, 2974-2974.	1.4	13
192	Characterization of CD20 expression loss as a mechanism of resistance to mosunetuzumab in patients with relapsed/refractory B-cell non-Hodgkin lymphomas.. Journal of Clinical Oncology, 2022, 40, 7526-7526.	1.6	13
193	Therapies for Relapsed Hodgkin Lymphoma: Transplant and Non-Transplant Approaches Including Immunotherapy. Hematology American Society of Hematology Education Program, 2005, 2005, 245-251.	2.5	12
194	Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. Leukemia, 2021, 35, 2854-2861.	7.2	12
195	A Phase 1b Study Investigating the Combination of the Tetravalent Bispecific NK Cell Engager AFM13 and Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Updated Safety and Efficacy Data. Blood, 2018, 132, 1620-1620.	1.4	12
196	A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma.. Blood, 2009, 114, 3693-3693.	1.4	12
197	Identification of An Active, Well-Tolerated Dose of Pralatrexate In Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL): Final Results of a Multicenter Dose-Finding Study.. Blood, 2010, 116, 2800-2800.	1.4	12
198	Maintenance rituximab every 2 months is more toxic than every 3 months in patients with non-Hodgkin lymphoma. Blood, 2015, 125, 3354-3355.	1.4	11

#	Article	IF	Citations
199	Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignancies. Leukemia and Lymphoma, 2015, 56, 1151-1153.	1.3	11
200	ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study. Haematologica, 2019, 104, e65-e67.	3.5	11
201	Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma. Blood Advances, 2021, 5, 3623-3632.	5.2	11
202	SGN-30 (Anti-CD30 mAb) Has a Single-Agent Response Rate of 21% in Patients with Refractory or Recurrent Systemic Anaplastic Large Cell Lymphoma (ALCL).. Blood, 2006, 108, 2718-2718.	1.4	11
203	Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study Update. Blood, 2011, 118, 443-443.	1.4	11
204	High expression of nucleoside transporter protein hENT1 in Reedâ€“Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin â€“ A CALGB 59804 correlative study. Leukemia and Lymphoma, 2008, 49, 1202-1205.	1.3	10
205	Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with highâ€risk follicular lymphoma: CALGB 50904 (Alliance). Cancer, 2019, 125, 3378-3389.	4.1	10
206	Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Antiâ€“CD20-based Biological Therapy. American Journal of Surgical Pathology, 2021, 45, 384-393.	3.7	10
207	Brentuximab Vedotin with Chemotherapy in Adolescents and Young Adults (AYA) with Stage III or IV Hodgkin Lymphoma: A Subgroup Analysis from the Phase 3 Echelon-1 Study. Blood, 2018, 132, 1647-1647.	1.4	10
208	A Phase I Open Label Dose Escalation Study To Evaluate MEDI-507 in Patients with CD2-Positive T-Cell Lymphoma/Leukemia.. Blood, 2006, 108, 2727-2727.	1.4	10
209	A Phase II Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) Abexinostat (PCI-24781) in Relapsed/Refractory Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL). Blood, 2012, 120, 55-55.	1.4	10
210	MACOP-B Â± radiation therapy for diffuse large cell lymphoma. Analysis of the Stanford Results According to Prognostic Indices. Cancer, 1993, 71, 4034-4042.	4.1	9
211	Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: Results of CALGB 59906. Leukemia and Lymphoma, 2006, 47, 1511-1517.	1.3	9
212	Expression of TIA1 and PAX5 in Classical Hodgkin Lymphoma at Initial Diagnosis May Predict Clinical Outcome. Applied Immunohistochemistry and Molecular Morphology, 2016, 24, 383-391.	1.2	9
213	Fine-Tuning the Treatment of Hodgkinâ€™s Lymphoma. New England Journal of Medicine, 2016, 374, 2490-2492.	27.0	9
214	Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma. Expert Opinion on Biological Therapy, 2021, 21, 831-839.	3.1	9
215	Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma: Part 3 (Concurrent Dosing) Results and Updated Progression-Free Survival Results from Parts 1 and 2 (Staggered Dosing). Blood, 2018, 132, 1635-1635.	1.4	9
216	A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results.. Blood, 2012, 120, 2746-2746.	1.4	9

#	Article	IF	Citations
217	Phase 1 Clinical Results of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL). Blood, 2015, 126, 3991-3991.	1.4	9
218	A Phase I Trial of Ibrutinib Plus Palbociclib in Patients with Previously Treated Mantle Cell Lymphoma. Blood, 2016, 128, 150-150.	1.4	9
219	Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. Blood, 2016, 128, 4144-4144.	1.4	9
220	Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials. Journal of Clinical Oncology, 2023, 41, 336-342.	1.6	9
221	Where Does Brentuximab Vedotin Fit into the Management of Patients with Hodgkin Lymphoma?. Current Hematologic Malignancy Reports, 2012, 7, 179-185.	2.3	8
222	A Phase II Multicenter Study of Lenalidomide in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL): Preliminary Results. Blood, 2008, 112, 2595-2595.	1.4	8
223	Randomized Phase III Trial Comparing ABVD + Radiotherapy and the Stanford V Regimen In Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the US Intergroup Trial E2496. Blood, 2010, 116, 416-416.	1.4	8
224	Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL),. Blood, 2011, 118, 3711-3711.	1.4	8
225	Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma. Leukemia and Lymphoma, 2022, 63, 821-833.	1.3	8
226	Composite diffuse large B-cell lymphoma and precursor B lymphoblastic lymphoma presenting as a double-hit lymphoma with MYC and BCL2 translocation. Journal of Clinical Pathology, 2011, 64, 1032-1034.	2.0	7
227	Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 2199-2204.	2.0	7
228	Emerging role of novel therapies in Hodgkin lymphoma: proceed with caution. Hematology American Society of Hematology Education Program, 2017, 2017, 317-323.	2.5	7
229	Minimal activity of nanoparticle albumin-bound (nab) paclitaxel in relapsed or refractory lymphomas: results of a phase-I study. Leukemia and Lymphoma, 2018, 59, 357-362.	1.3	7
230	Serious Pulmonary Toxicity with SGN-30 and Gemcitabine, Vinorelbine, and Liposomal Doxorubicin in Patients with Relapsed/Refractory Hodgkin Lymphoma (HL): Cancer and Leukemia Group B (CALGB) 50502. Blood, 2008, 112, 232-232.	1.4	7
231	A Phase 2 Multicenter Study of Continuous Dose Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma. Blood, 2012, 120, 1623-1623.	1.4	7
232	Subcutaneous (SC) Administration of Mosunetuzumab with Cycle 1 Step-up Dosing Is Tolerable and Active in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphomas (R/R B-NHL): Initial Results from a Phase I/II Study. Blood, 2021, 138, 3573-3573.	1.4	7
233	Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551. Cancer Chemotherapy and Pharmacology, 2009, 63, 793-798.	2.3	6
234	Abstract CT146: First-in-human phase I combination of the IL-15 receptor super agonist complex ALT-803 with a therapeutic (anti-CD20) monoclonal antibody (mAb) for patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL). Cancer Research, 2018, 78, CT146-CT146.	0.9	6

#	Article	IF	Citations
235	Long-Term Follow-up of SWOG S0816: Response-Adapted Therapy for Stage III/IV Hodgkin Lymphoma Demonstrates Limitations of PET-Adapted Approach. Blood, 2018, 132, 929-929.	1.4	6
236	Bendamustine Is Safe and Effective in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma.. Blood, 2007, 110, 1351-1351.	1.4	6
237	Phase I Analysis of the Safety and Pharmacodynamics of the Novel Broad Spectrum Histone Deacetylase Inhibitor (HDACi) PCI-24781 in Relapsed and Refractory Lymphoma.. Blood, 2009, 114, 2726-2726.	1.4	6
238	Pralatrexate Is Effective as Second-Line Treatment Following Cyclophosphamide/Doxorubicin/Vincristine/Prednisone (CHOP) Failure In Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL). Blood, 2010, 116, 4882-4882.	1.4	6
239	Long-Term Remissions Observed in an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma.. Blood, 2012, 120, 2745-2745.	1.4	6
240	Brentuximab Vedotin Administered Before, During, and After Multi-Agent Chemotherapy In Patients (pts) With Newly-Diagnosed CD30+ Mature T- and NK-Cell Lymphomas. Blood, 2013, 122, 4386-4386.	1.4	6
241	Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib Dose-Escalation. Blood, 2015, 126, 2726-2726.	1.4	6
242	Limited-Stage Hodgkin Lymphoma: Optimal Chemotherapy and the Role of Radiotherapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, 374-380.	3.8	6
243	Salvage regimens for Hodgkin lymphoma. Clinical Advances in Hematology and Oncology, 2008, 6, 517-24.	0.3	6
244	Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e435-e442.	0.4	6
245	CELESTIMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab plus lenalidomide versus rituximab plus lenalidomide in patients with relapsed or refractory follicular lymphoma who have received â‰¥ 1 line of systemic therapy.. Journal of Clinical Oncology, 2022, 40, TPS7588-TPS7588.	1.6	6
246	Protein Losing Enteropathy Associated With Follicular Lymphoma of the Small Bowel. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 222-223.	1.3	5
247	A Phase I Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin's Lymphoma (HL). Blood, 2012, 120, 1644-1644.	1.4	5
248	The Role Of Body Mass Index In Survival Outcome For Lymphoma Patients: US Intergroup Experience. Blood, 2013, 122, 3060-3060.	1.4	5
249	Brentuximab Vedotin Monotherapy in DLBCL Patients with Undetectable CD30: Preliminary Results from a Phase 2 Study. Blood, 2014, 124, 629-629.	1.4	5
250	Frontline Treatment of CD30+ Peripheral T-Cell Lymphomas with Brentuximab Vedotin in Combination with CHP: 3-Year Durability and Survival Follow-up. Blood, 2015, 126, 1537-1537.	1.4	5
251	A Phase I Trial of Brentuximab Vedotin in Combination with Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Blood, 2015, 126, 3988-3988.	1.4	5
252	Polatuzumab Vedotin Combined with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) for Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase Ib/II Study. Blood, 2016, 128, 1853-1853.	1.4	5

#	Article	IF	Citations
253	Four-Year Survival and Durability Results of Brentuximab Vedotin in Combination with CHP in the Frontline Treatment of Patients with CD30-Expressing Peripheral T-Cell Lymphomas. Blood, 2016, 128, 2993-2993.	1.4	5
254	Updated results of a phase II trial of brentuximab vedotin combined with R-CHOP in frontline treatment of patients (pts) with high-intermediate/high-risk diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology, 2015, 33, 8506-8506.	1.6	5
255	Metabolic Biomarkers Assessed with PET/CT Predict Sex-Specific Longitudinal Outcomes in Patients with Diffuse Large B-Cell Lymphoma. Cancers, 2022, 14, 2932.	3.7	5
256	Treatment advances in non-Hodgkinâ€™s lymphoma. Expert Opinion on Pharmacotherapy, 2000, 1, 451-465.	1.8	4
257	Biologic Agents in the Management of Hodgkin Lymphoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 587-596.	4.9	4
258	Fifty Shades of GATA2 Mutation: A Case of Plasmablastic Lymphoma, Nontuberculous Mycobacterial Infection, and Myelodysplastic Syndrome. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e532-e535.	0.4	4
259	Optimizing Second-Line Therapy for Hodgkin Lymphoma: A Work in Progress. Journal of Clinical Oncology, 2021, 39, 3097-3103.	1.6	4
260	Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk or Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma (AFT-08). Blood, 2018, 132, 2964-2964.	1.4	4
261	Long Term Follow-up of a Phase 2 Study Examining Intratumoral G100 Alone and in Combination with Pembrolizumab in Patients with Follicular Lymphoma. Blood, 2018, 132, 2892-2892.	1.4	4
262	Brentuximab Vedotin Plus Chemotherapy in Patients with Advanced-Stage Classical Hodgkin Lymphoma (cHL): Evaluation of Modified Progression-Free Survival (mPFS) and Traditional PFS in the Phase 3 ECHELON-1 Study. Blood, 2018, 132, 2904-2904.	1.4	4
263	A Phase 1b Clinical Trial of Dacetuzumab in Combination with Rituximab and Gemcitabine: Multiple Responses Observed in Patients with Relapsed Diffuse Large B-Cell Lymphoma.. Blood, 2009, 114, 586-586.	1.4	4
264	Lymphoma in Pregnancy: Excellent Fetal Outcomes and Maternal Survival in a Large Multicenter Analysis. Blood, 2011, 118, 94-94.	1.4	4
265	Brentuximab Vedotin in Combination with RCHOP As Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study. Blood, 2014, 124, 1745-1745.	1.4	4
266	Brentuximab Vedotin with RCHOP As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL): Results from an Ongoing Phase 2 Study. Blood, 2015, 126, 814-814.	1.4	4
267	Brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma (HL): North American results.. Journal of Clinical Oncology, 2018, 36, 7541-7541.	1.6	4
268	Phase I study of the Bcl-2 inhibitor venetoclax with DA-EPOCH-R as initial therapy for aggressive B-cell lymphomas.. Journal of Clinical Oncology, 2020, 38, 8003-8003.	1.6	4
269	Forodesine, a Purine Nucleoside Phosphorylase (PNP) Inhibitor, Shows Clinical Activity In a Phase 2 Trial In Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL) â€“ Interim Analysis. Blood, 2010, 116, 1397-1397.	1.4	4
270	Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): One-Year Follow-up of ZUMA-1 Cohort 6 (C6). Blood, 2021, 138, 2832-2832.	1.4	4

#	Article	IF	Citations
271	Novel Genetic Subgroups Inform on Shared Pathobiology within Adult and Pediatric Burkitt Lymphoma. Blood, 2021, 138, 806-806.	1.4	4
272	Blinatumomab Consolidation Post Autologous Hematopoietic Stem Cell Transplantation in Patients with Diffuse Large B Cell Lymphoma. Blood, 2020, 136, 3-4.	1.4	4
273	The Present: Optimizing Therapyâ€"Too Much or Too Little?. Hematology American Society of Hematology Education Program, 2010, 2010, 108-114.	2.5	3
274	Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma. OncoTargets and Therapy, 2016, 9, 2027.	2.0	3
275	SOHO State of the Art Updates and Next Questions: Hodgkin Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 81-90.	0.4	3
276	A Pilot Study of Lenalidomide Maintenance Therapy after Autologous Transplantation in Relapsed or Refractory Classical Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2020, 26, 2223-2228.	2.0	3
277	The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas. Blood, 2018, 132, 997-997.	1.4	3
278	Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus Lenalidomide in the Phase III Relevance Trial. Blood, 2019, 134, 1524-1524.	1.4	3
279	The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672). Blood, 2019, 134, 1591-1591.	1.4	3
280	Immuno-Chemotherapy (IC) and Autologous Stem Cell Transplant (ASCT) for Untreated Patients (pts) with Mantle Cell Lymphoma (MCL): CALGB 59909.. Blood, 2006, 108, 2737-2737.	1.4	3
281	Pralatrexate Is Effective In Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) with Prior Ifosfamide, Carboplatin, and Etoposide (ICE)-Based Regimens. Blood, 2010, 116, 1753-1753.	1.4	3
282	Patterns of Failure in Patients with Stage I/II Bulky Mediastinal Hodgkin Lymphoma (HL) Treated with ABVD + Radiotherapy or the Stanford V Regimen in the Randomized Phase III North American Intergroup Trial: E2496. Blood, 2011, 118, 1603-1603.	1.4	3
283	Interim FDG PET Imaging in CALGB 50203 Trial of Stage I/II Non-Bulky Hodgkin Lymphoma: Would Using Combined PET and CT Criteria Better Predict Response Than Each Test Alone?,. Blood, 2011, 118, 3644-3644.	1.4	3
284	Evaluation Of a Novel 3 Factor Prognostic Score (PS-3) For Patients With Advanced Hodgkin Lymphoma (HL) Treated On US Intergroup E2496. Blood, 2013, 122, 4277-4277.	1.4	3
285	A Phase I/II Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkinâ€™s Lymphoma (HL). Blood, 2014, 124, 3099-3099.	1.4	3
286	Phase II Trial of Ofatumumab (OFA) in Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL): CALGB 50901 (Alliance). Blood, 2015, 126, 2741-2741.	1.4	3
287	Early Relapse of Follicular Lymphoma after Rituximab-Based Biologic Doublet Upfront Therapy Is Associated with Increased Risk of Death: A Combined Analysis from CALGB Studies 50402, 50701 and 50803 (Alliance). Blood, 2016, 128, 2953-2953.	1.4	3
288	Banoxantrone (AQ4N), a Tissue Targeted Prodrug: Results of a Phase 1 Study in Lymphomas.. Blood, 2006, 108, 2429-2429.	1.4	3

#	Article	IF	Citations
289	Frontline Therapy of Nodular Lymphocyte Predominant Hodgkin Lymphoma with Rituximab: The Stanford University Experience. Blood, 2011, 118, 2686-2686.	1.4	3
290	Six-Year Results from the Phase 3 Randomized Study Relevance Show Similar Outcomes for Previously Untreated Follicular Lymphoma Patients Receiving Lenalidomide Plus Rituximab (R 2) Versus Rituximab-Chemotherapy Followed By Rituximab Maintenance. Blood, 2021, 138, 2417-2417.	1.4	3
291	Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey. Blood Advances, 2022, 6, 2745-2756.	5.2	3
292	Treatment of aggressive histology lymphoma. Current Opinion in Oncology, 1997, 9, 413-419.	2.4	2
293	Hodgkinâ€™s disease: Prognostic factors and short-course regimens. Current Oncology Reports, 2000, 2, 163-171.	4.0	2
294	Limited-Stage Hodgkin Lymphoma: Optimal Chemotherapy and the Role of Radiotherapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , 374-380.	3.8	2
295	Magnetic resonance image guided radiation therapy for primary splenic diffuse large B-cell lymphoma: A teaching case. Practical Radiation Oncology, 2017, 7, e23-e26.	2.1	2
296	Protect our children: Hodgkin lymphoma survivors. Blood, 2021, 137, 1433-1434.	1.4	2
297	Brentuximab vedotin in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (Trials in Progress).. Journal of Clinical Oncology, 2021, 39, TPS7571-TPS7571.	1.6	2
298	Survival after autologous versus allogeneic transplantation in patients with relapsed and refractory Hodgkin lymphoma. Leukemia and Lymphoma, 2021, 62, 2408-2415.	1.3	2
299	CD3xCD20 bispecific T-cell redirectors for relapsed or refractory B-cell lymphoma. Lancet, The, 2021, 398, 1109-1110.	13.7	2
300	Management of Advanced Stage Hodgkinâ€™s Lymphoma. , 2006, 131, 333-352.		2
301	Potential Impact of Consolidation Radiation Therapy for Advanced Hodgkin Lymphoma: A Secondary Modeling of SWOG S0816 with Receiver Operating Characteristic Analysis. Blood, 2018, 132, 2927-2927.	1.4	2
302	End of Treatment Peripheral Blood T-Cell Receptor Gene Rearrangement Evaluation for Minimal Residual Disease Evaluation in Peripheral T-Cell Lymphomas. Blood, 2020, 136, 30-31.	1.4	2
303	Retrospective Analysis of the Safety and Efficacy of Brentuximab Vedotin in Patients Aged 60 Years or Older with Relapsed or Refractory CD30+ Hematologic Malignancies. Blood, 2012, 120, 3687-3687.	1.4	2
304	Lack Of Clinical Benefit For Routine Surveillance Imaging For Diffuse Large B-Cell Lymphoma In First Complete Remission. Blood, 2013, 122, 4303-4303.	1.4	2
305	Insights into the Management of Adverse Events in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Experience from the Phase 3 HELIOS Study of Ibrutinib Combined with Bendamustine/Rituximab. Blood, 2015, 126, 2936-2936.	1.4	2
306	Interfollicular CD10 Expression and Follicular PD1 Tumor-Infiltrating Lymphocytes As Biologic Risk Factors in Patients with Previously Untreated Follicular Lymphoma Receiving Rituximab-Based Biologic Therapy: An Alliance Correlative Science Study (CALGB 50901, 50402, 50701, 50803, 50401). Blood, 2015, 126, 334-334.	1.4	2

#	Article	IF	Citations
307	Results from the International, Randomized Phase 3 Study of Ibrutinib Versus Chlorambucil in Patients 65 Years and Older with Treatment-NaÃ¯ve CLL/SLL (RESONATE-2TM). Blood, 2015, 126, 495-495.	1.4	2
308	Recurrent Somatic Genomic Alterations in Follicular NHL (FL) Revealed By Exome and Custom-Capture Next Generation Sequencing. Blood, 2015, 126, 574-574.	1.4	2
309	PIK3IP1 Inhibition of PI3K in G1 Arrest Induced By CDK4 Inhibition Reprograms MCL for Ibrutinib Therapy. Blood, 2016, 128, 610-610.	1.4	2
310	Ongoing complete remissions (CR) in the phase 1 of ZUMA-1: a phase 1-2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in subjects with refractory aggressive B-cell Non-Hodgkin Lymphoma (NHL).. Journal of Clinical Oncology, 2016, 34, 7559-7559.	1.6	2
311	Intratumoral G100 to induce systemic immune responses and abscopal tumor regression in patients with follicular lymphoma.. Journal of Clinical Oncology, 2017, 35, 7537-7537.	1.6	2
312	The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A randomized phase 2 study of CDX-1127 (varlilumab) in combination with nivolumab in patients with relapsed or refractory aggressive B-cell lymphomas (NCI 10089/NCT03038672).. Journal of Clinical Oncology, 2019, 37, TPS7570-TPS7570.	1.6	2
313	Gray Zone Lymphoma (GZL) With Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): A Large Retrospective Multicenter Analysis Of Clinical Characteristics, Treatment, Outcomes, and Prognosis In The Current Era. Blood, 2013, 122, 847-847.	1.4	2
314	Phase 1 Biomarker Analysis of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL). Blood, 2015, 126, 2730-2730.	1.4	2
315	The Echelon-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma. Blood, 2021, 138, 135-135.	1.4	2
316	Results of the DIAL study (NCI 10089), a randomized phase 2 trial of varlilumab combined with nivolumab in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (r/r B-NHL).. Journal of Clinical Oncology, 2022, 40, LBA7564-LBA7564.	1.6	2
317	To the Editor, A multicenter, open-label, early access treatment protocol for ibrutinib in patients with relapsed or refractory mantle cell lymphoma. Journal of Oncology Pharmacy Practice, 2019, 25, 1027-1030.	0.9	1
318	Approaches to aggressive B-cell lymphomas in less fit patients. Hematology American Society of Hematology Education Program, 2020, 2020, 140-147.	2.5	1
319	Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816. Leukemia and Lymphoma, 2020, 61, 2442-2447.	1.3	1
320	The justification of vincristine dose capping: tradition, traditionâ€¦tradition!. Leukemia and Lymphoma, 2020, 61, 1007-1009.	1.3	1
321	Treatment of Nodular Lymphocyte Hodgkin Lymphoma: The Goldilocks Principle. Journal of Clinical Oncology, 2020, 38, 662-668.	1.6	1
322	A forgotten friend: CCNU as palliative monotherapy in relapsed Hodgkin lymphoma. Leukemia and Lymphoma, 2021, 62, 486-488.	1.3	1
323	Prognostic Significance of PET Imaging in Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Salvage Chemotherapy and Autologous Stem Cell Transplantation.. Blood, 2009, 114, 3417-3417.	1.4	1
324	Pralatrexate Reverses the Trend to Progressive Resistance to Successive Systemic Treatment Regimens In Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL). Blood, 2010, 116, 4881-4881.	1.4	1

#	Article	IF	Citations
325	A Gene Expression Signature in Diagnostic Formalin Fixed Paraffin Embedded Tissue Predicts Overall Survival in Locally Advanced and Advanced Stage Classical Hodgkin Lymphoma â€“ a Correlative Study From the E2496 Intergroup Trial. Blood, 2011, 118, 430-430.	1.4	1
326	Toxicities and Related Outcomes of Elderly Patients (pts) (â‰¥65 Years) with Hematologic Malignancies in the Contemporary Era (Alliance A151611). Blood, 2016, 128, 536-536.	1.4	1
327	Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.4	1
328	Defining the Malignant Epigenome in Non-Hodgkin Lymphoma. Blood, 2012, 120, 524-524.	1.4	1
329	Safety Results from the United States Cohort of the Ibrutinib Early Access Treatment Protocol (EAP:) Tj ETQq1 1 0.784314 rgBT /Over	1.4	1
330	Outcomes in Adolescents and Young Adults (AYA) with Hodgkin Lymphoma (HL) Treated on US Cooperative Group Protocols: An Adult Intergroup (E2496) and Children's Oncology Group (COG) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.4	
331	Improvement of Quality of Response with Ibrutinib Plus Bendamustine/Rituximab Vs Placebo Plus Bendamustine/Rituximab for Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). Blood, 2015, 126, 2938-2938.	1.4	1
332	Ironclad: A randomized phase III study of ibrutinib (Ibr) or no consolidation following autologous hematopoietic stem cell transplantation (AutoHCT) for relapsed/refractory activated-B-cell (ABC) subtype diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology, 2017, 35, TPS7566-TPS7566.	1.6	1
333	Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas. Blood, 2019, 134, 1550-1550.	1.4	1
334	Relevance of bone marrow biopsies for response assessment in NCTN follicular lymphoma clinical trials.. Journal of Clinical Oncology, 2020, 38, 8038-8038.	1.6	1
335	Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.4	1
336	Brentuximab Vedotin in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ECHELON-3, Trial in Progress). Blood, 2021, 138, 3564-3564.	1.4	1
337	Treatment of nodular lymphocyte-predominant Hodgkin lymphoma-"do no harm". Clinical Advances in Hematology and Oncology, 2013, 11, 385-7.	0.3	1
338	Highlights in lymphoma from the 2013 American Society of Hematology Annual Meeting and Exposition: commentary. Clinical Advances in Hematology and Oncology, 2014, 12 Suppl 6, 18-23.	0.3	1
339	COVID-19 booster vaccines generate seroconversion in subset of patients with lymphoma/CLL: single institution experience. Leukemia and Lymphoma, 2022, 63, 1723-1727.	1.3	1
340	Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Safety and efficacy results from the safety run-in period of the phase 3 ECHELON-3 study.. Journal of Clinical Oncology, 2022, 40, 7559-7559.	1.6	1
341	90Yttriumâ€“ibritumomab tiuxetan: a novel treatment for non-Hodgkinâ€™s lymphoma. Expert Opinion on Biological Therapy, 2004, 4, 1323-1331.	3.1	0
342	Solid, Low-Attenuation Splenic Lesions on Computed Tomography in Patients With Indolent Lymphoma Often Signal Transformation: A Series of Ten Patients. Clinical Lymphoma, Myeloma and Leukemia, 2012, 12, 452-454.	0.4	0

#	Article	IF	Citations
343	A Young Woman With Blurred Vision and Distal Paresthesias. JAMA Neurology, 2015, 72, 1519.	9.0	0
344	Reply to T.M. Weis et al. Journal of Clinical Oncology, 2019, 37, 2953-2953.	1.6	0
345	Brentuximab vedotin with chemotherapy in adolescents and young adults (AYAs) with stage III or IV Hodgkin lymphoma: A subgroup analysis from the phase 3 Echelon-1 study.. Journal of Clinical Oncology, 2021, 39, 7528-7528.	1.6	0
346	A Phase II Study of Xcellerated T Cellsâ„¢ in Patients with Relapsed or Refractory Indolent Non-Hodgkinâ€™s Lymphoma (NHL).. Blood, 2004, 104, 4640-4640.	1.4	0
347	Validation of the International Harmonization Project (IHP) Guidelines in Early Stage Hodgkin Lymphoma (HL) Treated with Adriamycin, Vinblastine and Gemcitabine (AVG) (CALGB 50203): Early Results.. Blood, 2008, 112, 1460-1460.	1.4	0
348	Clonal Ig DNA Detection In Plasma From Patients with Untreated Diffuse Large B-Cell Lymphoma (DLBCL). Blood, 2010, 116, 3127-3127.	1.4	0
349	Second Cancers After Treatment with Stanford V Regimen in Eastern Cooperative Oncology Group (ECOG) Pilot Study E1492 At a Median Follow up of 17 Years. Blood, 2012, 120, 4779-4779.	1.4	0
350	Lymphoma Surveillance Counterpoint: USA. , 2013, , 461-466.		0
351	Minimal Residual Disease Measurement By Deep Sequencing Reflects Changes In Disease Load During Therapy In Diffuse Large B Cell Lymphoma Patients. Blood, 2013, 122, 1785-1785.	1.4	0
352	Gray Zone Lymphoma (GZL) with Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of Tumor Immunophenotype (IP) and Critical Examination of Therapy with Associated Impact on Outcome. Blood, 2014, 124, 1703-1703.	1.4	0
353	Long-Term Outcomes, Secondary Malignancies, and Stem Cell Collection Following Bendamustine in Patients with Previously Treated Indolent Non-Hodgkin Lymphoma. Blood, 2015, 126, 3961-3961.	1.4	0
354	Regulatory T Cells Are Depleted in Low-Grade Lymphoma By the Combination of Local Low-Dose Radiation Followed By Intratumoral CpG-ODN. Blood, 2015, 126, 1539-1539.	1.4	0
355	Systemic Exposure of Rituximab Increased By Ibrutinib: Pharmacokinetic Results from the Helios Trial. Blood, 2016, 128, 4403-4403.	1.4	0
356	Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas Including AITL and DLBCL: Phase I Results. Blood, 2018, 132, 2929-2929.	1.4	0
357	Short Diagnosis to Treatment Interval (DTI) Is Associated with Inferior Outcome in Newly Diagnosed Patients with Mantle Cell Lymphoma, a MER/LEO and Alliance Collaboration. Blood, 2018, 132, 2878-2878.	1.4	0
358	Impact of Rituximab Infusion Reactions on Clinical Outcomes in Patients with Diffuse Large B-Cell Lymphoma. Blood, 2018, 132, 4203-4203.	1.4	0
359	Fitness and Anthracycline Use in Front-Line Therapy for Older Patients with Classical Hodgkin Lymphoma: A US Multi-Center Retrospective Analysis. Blood, 2019, 134, 4027-4027.	1.4	0
360	Composite Copy Number Variation in CDK4, CDKN2A and RB1 Predisposes Mantle Cell Lymphoma to Expansion of PD1+ Tumor Cells and Resistance to CDK4/6 Inhibitor Therapy as Revealed by Integrative Longitudinal scRNA-seq. Blood, 2019, 134, 1492-1492.	1.4	0

#	Article	IF	Citations
361	North American Practice Patterns for PET-2 Positive Hodgkin Lymphoma. Blood, 2019, 134, 1553-1553.	1.4	0
362	Prognostic Factors Other Than Age Drive the Risk of Disease Progression in Adults with Burkitt Lymphoma Treated with DA-EPOCH-R. Blood, 2021, 138, 453-453.	1.4	0
363	Local Review Versus (vs) Central Review of Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in Diffuse Large B-Cell Lymphoma (DLBCL): Results from the CALGB 50303 Trial [Alliance]. Blood, 2020, 136, 50-50.	1.4	0
364	Patient-Specific Metabolism Assessed By Visceral Fat and Diabetes May Alter Prognosis in Relapsed/Refractory Hodgkin Lymphoma. Blood, 2020, 136, 30-31.	1.4	0
365	Stem cell transplant for lymphoma - never too late?. Haematologica, 2022, , .	3.5	0
366	Advances in LLM: Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. Clinical Advances in Hematology and Oncology, 2012, 10, 468-71.	0.3	0
367	Commentary. Clinical Advances in Hematology and Oncology, 2014, 12, 18-23.	0.3	0
368	Radiation for early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a double-edged sword?. Leukemia and Lymphoma, 2016, 57, 249-251.	1.3	0
369	Alliance A059102: A randomized phase II U.S. intergroup study of CHO(E)P versus CC-486-CHO(E)P versus duvelisib-CHO(E)P in previously untreated, CD30-negative, peripheral T-cell lymphomas.. Journal of Clinical Oncology, 2022, 40, TPS7593-TPS7593.	1.6	0